Study of the Effectiveness and Safety of Darunavir/Cobicistat (DRV/c) Containing Regimens in Routine Clinical Practice (CoDAR)

Fundacion SEIMC-GESIDA

Status: Completed

Conditions: HIV Infections

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT03042390

GESIDA 9316

Details and patient eligibility

About

This is a retrospective observational study of patients who have taken a regimen containing DRV / c at least 24 weeks prior to study initiation

Full description

The study will include 750 patients and will record data at 24 weeks. The study will also record data at 48 weeks for those patients whom these data are available

Enrollment: 762 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with HIV infection
• Inform consent document.
• To have initiated therapy containing DRV / c and have a follow-up of at least 24 Weeks.

Exclusion criteria

• Not having evaluable clinical data of the patient
• Patients not routinely followed in the center
• Patient less than 18 years of age.

Trial design

762 participants in 1 patient group

DArunavir/cobicistat

Description:

Patients starting treatment with a regimen containing Darunavir / cobicistat for at least 24 weeks